AKT1 and neoplasm: As shown in Figure 3B, the triple-drug combination significantly (p < 0.0001) reduced the gene expression levels of VEGF, VEGFR, PI3K, PDK1, AKT1, mTOR and GSK3β while it significantly (p < 0.0001) enhanced the expression of PTEN, when compared with the tumor-control (TC) and other treatment groups.